Further developments with antisense treatment for myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1275, Issue 1, 2012, Pages 13-16

  Sussman, Jon ^a   Argov, Zohar ^b   Wirguin, Yitzhak ^c   Apolski, Slobodan ^d   Milic Rasic, Vedrana ^e   Soreq, Hermona ^f  

^a Greater Manchester Neurosciences Centre   (United Kingdom)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e Clinic for Neurology and Psychiatry   (Serbia)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Acetylcholinesterase; Antisense; Read through transcript; TLR9

Indexed keywords

ACETYLCHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDE; EN 101; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PYRIDOSTIGMINE; UNCLASSIFIED DRUG;

ADULT; ANTISENSE THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MYASTHENIA GRAVIS; PHASE 2 CLINICAL TRIAL; SCORING SYSTEM; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 84871567801     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06825.x     Document Type: Article

References (13)

1. Li, Y., S. Camp, T.L. Rachinsky, et al. 1991. Gene structure of mammalian acetylcholinesterase. Alternative exons dictate tissue-specific expression. J. Biol. Chem. 266: 23083-23090.
2. Grisaru, D., M. Sternfeld, A. Eldor, et al. 1999. Structural roles of acetylcholinesterase variants in biology and pathology. Eur. J. Biochem. 264: 672-686.
3. Seidman, S., M., Sternfeld, R. Ben Aziz-Aloya, et al. 1995. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3′-terminal exons. Mol. Cell. Biol. 15: 2993-3002.
4. Soreq, H. & S. Seidman. 2001. Acetylcholinesterase-new roles for an old actor. Nat. Neurosci. Rev. 2: 294-302.
5. Brenner, T., Y. Hamra-Amitay, T. Evron, et al. 2003. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 17: 214-222.
6. Boneva, N., Y. Hamra-Amitay, I. Wiruin, et al. 2006. Stimulated-single fiber electromyography monitoring of anti-sense induced changes in experimental autoimmune myasthenia gravis. Neurosci. Res. 55: 40-44.
7. Pollak, Y., A. Gilboa, O. Ben-Menachem, et al. 2005. Acetylcholinesterase modulates interleukin-1β production in the hippocampus and blood. Ann. Neurol. 57: 741-745.
8. Argov, Z., D. McKee, S. Agus, et al. 2007. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69: 699-700.
9. Grifman, M. & H. Soreq. 1997. Differentiation intensifies the susceptibility of phaeochromocytoma cells to antisense oligodeoxynucleotide-dependent suppression of acetylcholinesterase activity. Antisense Res. Nucleic Acids Drug Dev. 7: 351-359.
10. Galyam, N., D. Grisaru, N. Melamed-Book, et al. 2001. Complex host cell responses to antisense suppression of ACHE gene expression. Antisense Nucleic Acid Drug Dev. 11: 51-57.
11. Agrawal S. & E.R. Kandimalla. 2004. Role of Toll-like receptors in antisense and siRNA. Nat. Biotechnol. 22: 1533-7. Erratum in Nat. Biotechnol. 2005 Jan; 23 (1): 117.
12. Gilboa-Geffen A., Y. Wolf, G. Hanin, et al. 2011. Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjögren's syndrome. PLoS One 6: e28727.
13. Evron, T., L. Ben-Moyal, N. Lam, et al. 2005. RNA-targeted suppression of stress-induced allostasis in monkey spinal cord neurons. Neurodegenerat. Dis. 2: 16-27.